Yes, and no. The company has said they will use date from the Rosacea Ph2 to build on Acne Ph3, but there is no reason anti-microbial couldn't run simultaneously to either acne or rosacea, other than funding. It speaks for itself that we are currently not running ANY trials whilst waiting approval for Sofdra, ONLY because we don't have the funds - nothing to do with evidence & learning. It will be the same going forward (other than the rosacea/acne connection acknowledged), but I daresay if we had the funds, you would see more than one trial on the go.
BOT - Anything but charting, page-6928
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
-0.005(1.47%) |
Mkt cap ! $608.8M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 34.3¢ | 32.5¢ | $1.200M | 3.588M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 349093 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 25403 | 5 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |